



Tobacco control: all research, no action



Pikist/Keppel/Shutterstock

Published Online
May 27, 2021
[https://doi.org/10.1016/S0140-6736\(21\)01193-4](https://doi.org/10.1016/S0140-6736(21)01193-4)

See **Articles** page 2337

For more on the 1998 Master Settlement Agreement see <https://www.publichealthlawcenter.org/topics/commercial-tobacco-control/commercial-tobacco-control-litigation/master-settlement-agreement>

In a sobering Article in *The Lancet*, the GBD 2019 Tobacco Collaborators¹ refine methods to estimate the increasing toll of tobacco-attributable morbidity and mortality. The authors analysed data on prevalence of smoking tobacco use from 204 countries and territories between 1990 and 2019, based on information from 3625 self-reported nationally representative surveys. Their analysis, the second to focus on tobacco in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD),² improves on calculations of prevalence of smoking in adults and tobacco-related disease by adding over 800 data sources for prevalence and directly estimating the impact of smoking from Bayesian meta-regression analyses of 36 health outcomes.

The authors found that global age-standardised prevalence of smoking tobacco use decreased by 27.5% (95% uncertainty interval 26.5–28.5) in males and 37.7% (35.4–39.9) in females aged 15 years and older between 1990 and 2019.¹ However, inexorable population growth has increased the number of smokers from 0.99 billion (0.98–1.00) in 1990 to 1.14 billion (1.13–1.16) in 2019, who consumed 7.41 trillion (7.11–7.74) cigarette-equivalents of tobacco in 2019. The authors estimated that 5.96 million (77.5%) of 7.69 million smoking-attributable deaths in 2019 occurred in low-income and middle-income countries and that 66 (93%) of 71 countries that had significant increases in such deaths were low-income and middle-income countries.

A wide variation in prevalence of smoking tobacco use was found in these countries that obscures an understanding of the individual-level factors. For instance, WHO reported that although global tobacco cultivation decreased by 15.7% between 2012 and 2018, it increased by 3.4% in Africa.³ The number of adult users of tobacco in Africa increased from 64 million in 2000 to 73 million in 2018,³ but population growth alone might not fully explain this increase. Affordability of cigarettes and economic reliance on tobacco farming to alleviate poverty could account for increasing consumption.

This Article by the GBD 2019 Tobacco Collaborators comprises descriptive statistics and is not analytical epidemiological research reporting causal inferences. For over 70 years, countless epidemiological studies

have informed us of the tragic toll of cigarette smoking. These latest findings remind us of the ongoing worldwide health crisis resulting from tobacco use. But in their minimal conclusion, the authors do not ask what, precisely, we must do with their data.

How to tackle the global smoking pandemic has become a perpetual dilemma. Tobacco control—a term adopted by 1990s academia to keep radical grassroots antismoking activism at arm’s length—remains mired in descriptive research that generates data to support policies aimed at reducing smoking. However, unlike, for instance, mosquito control, the vector—the tobacco industry—survives and thrives. And, like a mutating virus, it adapts to legislative and regulatory attempts to hinder the sale, promotion, and use of its products.

Taxation or sin taxes are not necessarily the most effective tobacco control policy, but to say so risks derision. Cigarette taxes could be set high enough to crush the tobacco industry, but no governments will go that far. They rely on this revenue for deficit reduction and for things other than curbing smoking.

The vaunted 1998 Master Settlement Agreement between the US state attorneys general and the tobacco industry, ostensibly to recover medical costs for disease caused by smoking, epitomises government addiction to tobacco money. States have spent only 3% of the annual payments to them from the industry to fight smoking, which in some instances is less than before the Master Settlement Agreement. Increases in tobacco taxation might have reduced sales to the poorest consumers, but US cigarette manufacturers are still making huge profits and tobacco stocks remain a healthy investment.⁴

The tobacco industry’s never-ending plea that more research is needed before restricting or banning its products has been heeded for too long. In 1985, US Surgeon General C Everett Koop pointed to the overwhelming scientific base—already more than 50 000 studies—linking smoking to various chronic diseases.⁵ A PubMed search on May 20, 2021, using the terms “smoking”, “cigarettes”, “tobacco”, and “e-cigarettes” yielded 358 858 publications since Jan 1, 1985. Are all these additional papers, and their funding, still insufficient?

Only in the mid-2000s did we begin to flatten the curve for lung cancer mortality for both men and

For more on lung cancer mortality see <https://canceratlas.cancer.org/the-burden/lung-cancer/>

women in the UK and the USA, long after the Royal College of Physicians and the US Surgeon General Luther Terry told us what we needed to do.⁶ By stark contrast with the trillions of dollars allocated by US Congress to address COVID-19, no major funding has ever been approved to fight smoking and its promotion.

The tobacco industry remains the foremost obstacle to tobacco control. State-owned cigarette manufacturers—notably, the China tobacco monopoly in the world's largest cigarette market—pose a daunting challenge to public health. The USA, the UK, Japan, South Korea, Switzerland, and Sweden, among other countries, also host powerful tobacco companies.

Unlike the earnest but static WHO Framework Convention on Tobacco Control, which has not been well implemented,⁷ the tobacco industry is dynamic and resilient. The livelihoods of 100 million people are dependent on the production, distribution, and sale of tobacco products.^{8,9} No jobs in tobacco control will be lost if smoking and the resultant diseases increase. Public health failures engender research funding.

Forget health ministers, legislators, and university trustees. Any hope for ending the tobacco pandemic lies in the commitment of every health professional to make smoking prevention, smoking cessation, and relapse prevention top priorities. Philanthropic foundations can best support this goal by shifting funds from research to hard-hitting, paid, mass media campaigns that indict tobacco companies, shatter myths (eg, that the filter makes smoking safer), and subvert cigarette sales through brand-name satire.¹⁰⁻¹²

We declare no competing interests.

*Alan Blum, Ransome Eke
ablum@ua.edu

Center for the Study of Tobacco and Society (AB) and Department of Health Science (RE), University of Alabama, Tuscaloosa, AL 35401, USA

- 1 GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet* 2021; published online May 27. [https://doi.org/10.1016/S0140-6736\(21\)01169-7](https://doi.org/10.1016/S0140-6736(21)01169-7)
- 2 GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet* 2017; **389**: 1885–906.
- 3 Anon. Tobacco cultivation up in Africa, down globally. *Tobacco Reporter*, April, 2021. <https://www.tobaccoreporter.com/digital/april21/> (accessed May 18, 2021).
- 4 Maloney J, Chaudhuri S. Against all odds, the US tobacco industry is rolling in money. *Wall Street Journal*, April 23, 2017. <https://www.wsj.com/articles/u-s-tobacco-industry-rebounds-from-its-near-death-experience-1492968698#:~:text=The%20operating%20profits%20of%20U.S.,America%20Merrill%20Lynch%20Global%20Research> (accessed May 18, 2021).
- 5 US Department of Health and Human Services, Public Health Service, Koop, CE. Statement of C. Everett Koop, M.D. Surgeon General Public Health Service U.S. Department of Health and Human Services before the subcommittee on governmental affairs U.S. Senate. Oct 1, 1985. <https://www.industrydocuments.ucsf.edu/tobacco/docs/#id=jgvr0111> (accessed May 20, 2021).
- 6 US Department of Health, Education, and Welfare, Smoking and Health: report of the advisory committee to the Surgeon General of the Public Health Service, 1964. Public Health Service Publication No. 1103. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service, 1964.
- 7 WHO launches new report on the global tobacco epidemic. Pan American Health Organization, July 26, 2019. https://www.paho.org/hq/index.php?option=com_content&view=article&id=15338:who-launches-new-report-on-the-global-tobacco-epidemic&Itemid=1926&lang=en (accessed May 18, 2021).
- 8 ILO: up in smoke: what future for tobacco jobs? Geneva: International Labour Organisation, Sept 18, 2003. https://www.ilo.org/global/about-the-ilo/mission-and-objectives/features/WCMS_071230/lang--en/index.htm (accessed May 18, 2021).
- 9 Sectoral Policies Department. Tobacco sector employment statistical update. Geneva: International Labour Organisation, 2014. https://www.ilo.org/wcmsp5/groups/public/---ed_dialogue/---sector/documents/publication/wcms_329284.pdf (accessed May 18, 2021).
- 10 Blum A. Medicine vs Madison Avenue. Fighting smoke with smoke. *JAMA* 1980; **243**: 739–40.
- 11 Blum A. Cigarette smoking and its promotion: editorials are not enough. *NY State J Med* 1983; **83**: 1245–47.
- 12 Blum A, Novotny T. The filter fraud: debunking the myth of "safer" as a key new strategy of tobacco control. *Tab Induc Dis* 2018; **16** (suppl 1): A81.

For the Royal College of Physicians statement on smoking and health from 1962 see <https://www.rcplondon.ac.uk/projects/outputs/smoking-and-health-1962>

Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma



In the rapidly evolving treatment landscape for multiple myeloma, the optimal choice and sequencing of drugs are challenging.¹⁻⁵ At the time of clinical relapse, a number of factors related to the host and the disease ultimately affects treatment selection.¹² However, the depth and duration of response, exposure to previous drugs, and refractoriness to one or more classes of

agents, particularly in the last treatment line, are crucial for the selection of the best sequence.³⁻⁵

In *The Lancet*, Philippe Moreau and colleagues⁶ report the results from an interim analysis of the phase 3 IKEMA study comparing isatuximab, carfilzomib, and dexamethasone (isatuximab group) versus carfilzomib and dexamethasone (control

Published Online
June 4, 2021
[https://doi.org/10.1016/S0140-6736\(21\)00729-7](https://doi.org/10.1016/S0140-6736(21)00729-7)
See **Articles** page 2361

THE LANCET

Volume 397 · Number 10 292 · Pages 2309–2438 · June 19–25, 2021

www.thelancet.com

“COVAX ‘was a beautiful idea, born out of solidarity. Unfortunately, it didn’t happen...Rich countries behaved worse than anyone’s worst nightmares.”

See [World Report](#) page 2322

Editorial

Protecting refugees during the COVID-19 pandemic
See page 2309

Articles

Global prevalence of smoking tobacco use and attributable disease burden
See page 2337

Articles

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma
See page 2361

Articles

Filgotinib as induction and maintenance therapy for ulcerative colitis
See page 2372

*****AUTO**ALL FOR ADC 350
001700472100
ALAN BLUM
26 PINEHURST DR
TUSCALOOSA AL 35401-1148

00001
000145
000145
000145

The Lancet (ISSN 0099-5355) is published weekly, except for the last issue in December which is a double issue, by Elsevier Ltd. © 2021 Elsevier Ltd. All rights reserved. Elsevier Ltd, 230 Park Avenue, Suite 800, New York, NY 10169, USA. Tel: 212-989-5800. Fax: 212-633-3990. Periodical postage paid at New York NY and additional mailing offices. #585-880 USA
POSTMASTER: Send address changes to The Lancet, Elsevier, Subscription Customer Service, 3251 Riverport Ln, Maryland Heights MO 63043, USA.
The Lancet is a trade mark of RELX Intellectual Properties SA, used under license. Printed in USA.

Founded 1823 · Published weekly